全文获取类型
收费全文 | 7484篇 |
免费 | 294篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 221篇 |
儿科学 | 257篇 |
妇产科学 | 92篇 |
基础医学 | 724篇 |
口腔科学 | 185篇 |
临床医学 | 845篇 |
内科学 | 2203篇 |
皮肤病学 | 16篇 |
神经病学 | 1611篇 |
特种医学 | 137篇 |
外科学 | 752篇 |
综合类 | 58篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 284篇 |
眼科学 | 38篇 |
药学 | 162篇 |
中国医学 | 32篇 |
肿瘤学 | 168篇 |
出版年
2024年 | 4篇 |
2023年 | 404篇 |
2022年 | 639篇 |
2021年 | 769篇 |
2020年 | 798篇 |
2019年 | 394篇 |
2018年 | 333篇 |
2017年 | 453篇 |
2016年 | 494篇 |
2015年 | 337篇 |
2014年 | 576篇 |
2013年 | 433篇 |
2012年 | 276篇 |
2011年 | 183篇 |
2010年 | 360篇 |
2009年 | 295篇 |
2008年 | 118篇 |
2007年 | 120篇 |
2006年 | 89篇 |
2005年 | 73篇 |
2004年 | 55篇 |
2003年 | 58篇 |
2002年 | 57篇 |
2001年 | 67篇 |
2000年 | 41篇 |
1999年 | 48篇 |
1998年 | 49篇 |
1997年 | 33篇 |
1996年 | 47篇 |
1995年 | 44篇 |
1994年 | 29篇 |
1993年 | 24篇 |
1992年 | 10篇 |
1991年 | 11篇 |
1990年 | 6篇 |
1989年 | 13篇 |
1988年 | 22篇 |
1987年 | 1篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 7篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有7787条查询结果,搜索用时 31 毫秒
1.
《International journal of oral and maxillofacial surgery》2022,51(3):332-337
The purpose of this study was to investigate the association between habitual snoring (HS), middle ear disease (MED), and speech problems in children with cleft palate. This cross-sectional study included children aged 2.0–7.9 years with non-syndromic cleft palate anomalies. Parents completed the Pediatric Sleep Questionnaire and a questionnaire about MED. Audiograms and speech assessment were also conducted. Ninety-five children were enrolled; 15.2% of families reported HS, 97.6% MED, and 17.1% speech problems. HS (37.5% vs 10.3%, P = 0.007) and early episodes of MED (92.3% vs 58.2%, P = 0.021) were more likely to be reported for children with isolated cleft palate when compared to those with cleft lip and palate. Children with cleft lip and palate had a higher frequency of MED with effusion compared to those with Robin sequence (86.4% vs 57.1%, P = 0.049). The odds ratio for HS in children with ≥1 episode of MED in the last year was 7.37 (95% confidence interval 1.55–35.15, P = 0.012). There was a trend for children with speech problems reported by parents to have HS (30.8% vs 11.5%, P= 0.076). Anatomical factors play a role in the frequency of upper airway symptoms in children with cleft palate. A recent history of at least one episode of MED was associated with an increased frequency of HS. 相似文献
2.
BackgroundLeft ventricular unloading with Impella may improve survival outcomes in patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS). However, the optimal timing to initiate left ventricular unloading has yet to be established. Therefore, we conducted a systematic review and meta-analysis to compare survival in patients with AMI-CS who were supported with Impella prior to PCI (pre-PCI) to those in whom support was initiated following PCI (post-PCI).MethodsAll studies that evaluated the impact of pre-PCI versus post-PCI Impella placement in patients with AMI-CS were included. Primary endpoints included in-hospital, 30-day, and 6-month survival rates.ResultsWe identified five observational studies comparing outcomes in 432 patients with AMI-CS, of which 173 patients were treated with Impella pre-PCI and 259 patients post-PCI. Patients in the pre-PCI group had lower in-hospital mortality compared to patients in the post-PCI group (RR 0.62, 95% CI: 0.50–0.76, I2 = 0%). The lower mortality rate in the pre-PCI group remained evident at 30 days (HR 0.60, 95% CI: 0.47–0.78, I2 = 0%) and at 6 months (HR 0.66, 95% CI: 0.44–0.97, I2 = 0%). There was no difference in the risk of adverse events including reinfarction, stroke, major bleeding, acute ischemic limb, access site bleeding, and hemolysis.ConclusionsIn this meta-analysis of studies evaluating survival among AMI-CS patients with left ventricular unloading initiated pre- versus post-PCI, Impella placement prior to PCI was associated with improved survival. 相似文献
3.
4.
5.
6.
7.
8.
《Archives of physical medicine and rehabilitation》2022,103(11):2265-2266
9.
10.
发作性睡病是致残性白天睡眠增多的最常见原因之一,其治疗旨在减少白天睡眠增多和猝倒,改善夜间睡眠紊乱、睡眠瘫痪及与睡眠有关的幻觉。2019年,组胺H3受体拮抗剂替洛利生(Pitolisant)和多巴胺及去甲肾上腺素再摄取抑制剂索利氨酯(Solriamfetol)分别在欧盟和美国上市,前者具有促醒和抗猝倒作用,后者也有促醒作用,且戒断症状和滥用的发生率更低。目前,控释型羟丁酸钠(FT218)、低钠型羟丁酸盐(JZP-258)、选择性去甲肾上腺素再摄取抑制剂(瑞波西汀,又称AXS-12)以及莫达非尼联合氟卡尼制剂(THN102)等药物仍在开发和测试中,均可作为治疗发作性睡病相关白天睡眠增多和猝倒的潜在药物。本文重点介绍这些最近研发的发作性睡病治疗药物。 相似文献